These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

919 related items for PubMed ID: 16757700

  • 1. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
    Merchan JR, Tang J, Hu G, Lin Y, Mutter W, Tong C, Karumanchi SA, Russell SJ, Sukhatme VP.
    J Natl Cancer Inst; 2006 Jun 07; 98(11):756-64. PubMed ID: 16757700
    [Abstract] [Full Text] [Related]

  • 2. Effect of disrupted SOX18 transcription factor function on tumor growth, vascularization, and endothelial development.
    Young N, Hahn CN, Poh A, Dong C, Wilhelm D, Olsson J, Muscat GE, Parsons P, Gamble JR, Koopman P.
    J Natl Cancer Inst; 2006 Aug 02; 98(15):1060-7. PubMed ID: 16882943
    [Abstract] [Full Text] [Related]

  • 3. Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
    Mitra SK, Lim ST, Chi A, Schlaepfer DD.
    Oncogene; 2006 Jul 27; 25(32):4429-40. PubMed ID: 16547501
    [Abstract] [Full Text] [Related]

  • 4. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
    Krüger A, Soeltl R, Lutz V, Wilhelm OG, Magdolen V, Rojo EE, Hantzopoulos PA, Graeff H, Gänsbacher B, Schmitt M.
    Cancer Gene Ther; 2000 Feb 27; 7(2):292-9. PubMed ID: 10770639
    [Abstract] [Full Text] [Related]

  • 5. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
    Frandsen TL, Holst-Hansen C, Nielsen BS, Christensen IJ, Nyengaard JR, Carmeliet P, Brünner N.
    Cancer Res; 2001 Jan 15; 61(2):532-7. PubMed ID: 11212246
    [Abstract] [Full Text] [Related]

  • 6. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B, Nakamura M, Zhou G, Ishii A, Nakamura A, Bai Y, Mori I, Kakudo K.
    Int J Oncol; 2006 Apr 15; 28(4):807-14. PubMed ID: 16525628
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effects of Mucin 1/sec involves the modulation of urokinase-type plasminogen activator and signal transducer and activator of transcription 1 expression in tumor cells.
    Ilkovitch D, Handel-Fernandez ME, Herbert LM, Lopez DM.
    Cancer Res; 2008 Apr 01; 68(7):2427-35. PubMed ID: 18381451
    [Abstract] [Full Text] [Related]

  • 8. Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice.
    Lamszus K, Jin L, Fuchs A, Shi E, Chowdhury S, Yao Y, Polverini PJ, Laterra J, Goldberg ID, Rosen EM.
    Lab Invest; 1997 Mar 01; 76(3):339-53. PubMed ID: 9121117
    [Abstract] [Full Text] [Related]

  • 9. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes.
    Yu HR, Schultz RM.
    Cancer Res; 1990 Dec 01; 50(23):7623-33. PubMed ID: 1701350
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.
    Kobayashi H, Gotoh J, Shinohara H, Moniwa N, Terao T.
    Thromb Haemost; 1994 Apr 01; 71(4):474-80. PubMed ID: 8052966
    [Abstract] [Full Text] [Related]

  • 11. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
    Guo Y, Mazar AP, Lebrun JJ, Rabbani SA.
    Cancer Res; 2002 Aug 15; 62(16):4678-84. PubMed ID: 12183425
    [Abstract] [Full Text] [Related]

  • 12. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
    Ishii Y, Pirkmaier A, Alvarez JV, Frank DA, Keselman I, Logothetis D, Mandeli J, O'Connell MJ, Waxman S, Germain D.
    J Natl Cancer Inst; 2006 Sep 06; 98(17):1238-47. PubMed ID: 16954476
    [Abstract] [Full Text] [Related]

  • 13. Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells.
    Mohanam S, Jasti SL, Kondraganti SR, Chandrasekar N, Kin Y, Fuller GN, Lakka SS, Kyritsis AP, Dinh DH, Olivero WC, Gujrati M, Yung WK, Rao JS.
    Clin Cancer Res; 2001 Aug 06; 7(8):2519-26. PubMed ID: 11489835
    [Abstract] [Full Text] [Related]

  • 14. Changes in vessel wall plasminogen activator activity and smooth muscle cell proliferation and activation after arterial injury.
    More RS, Underwood MJ, Brack MJ, de Bono DP, Gershlick AH.
    Cardiovasc Res; 1995 Jan 06; 29(1):22-6. PubMed ID: 7895234
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis.
    Hajitou A, Sounni NE, Devy L, Grignet-Debrus C, Lewalle JM, Li H, Deroanne CF, Lu H, Colige A, Nusgens BV, Frankenne F, Maron A, Yeh P, Perricaudet M, Chang Y, Soria C, Calberg-Bacq CM, Foidart JM, Noël A.
    Cancer Res; 2001 Apr 15; 61(8):3450-7. PubMed ID: 11309307
    [Abstract] [Full Text] [Related]

  • 17. Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells.
    Azuma H, Ehata S, Miyazaki H, Watabe T, Maruyama O, Imamura T, Sakamoto T, Kiyama S, Kiyama Y, Ubai T, Inamoto T, Takahara S, Itoh Y, Otsuki Y, Katsuoka Y, Miyazono K, Horie S.
    J Natl Cancer Inst; 2005 Dec 07; 97(23):1734-46. PubMed ID: 16333029
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver.
    Gray MJ, Van Buren G, Dallas NA, Xia L, Wang X, Yang AD, Somcio RJ, Lin YG, Lim S, Fan F, Mangala LS, Arumugam T, Logsdon CD, Lopez-Berestein G, Sood AK, Ellis LM.
    J Natl Cancer Inst; 2008 Jan 16; 100(2):109-20. PubMed ID: 18182619
    [Abstract] [Full Text] [Related]

  • 19. Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma.
    Todaro LB, Ladeda V, Bal de Kier Joffé E, Farías EF.
    Oncol Rep; 2003 Jan 16; 10(3):725-32. PubMed ID: 12684650
    [Abstract] [Full Text] [Related]

  • 20. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
    Rabbani SA, Gladu J.
    Cancer Res; 2002 Apr 15; 62(8):2390-7. PubMed ID: 11956102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.